NON-HODGKIN'S LYMPHOMA
Clinical trials for NON-HODGKIN'S LYMPHOMA explained in plain language.
Never miss a new study
Get alerted when new NON-HODGKIN'S LYMPHOMA trials appear
Sign up with your email to follow new studies for NON-HODGKIN'S LYMPHOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
Could a drug make stem cell transplants safer for blood cancer patients?
Disease control CompletedThis study tested a drug called palifermin in 34 adults with blood cancers who received stem cells from an unrelated donor. The goal was to see if palifermin could reduce severe graft-versus-host disease (GVHD), a common complication where donor cells attack the patient's body. P…
Matched conditions: NON-HODGKIN'S LYMPHOMA
Phase: PHASE1, PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 26, 2026 05:53 UTC
-
Experimental cancer vaccine combo shows promise in small trial
Disease control CompletedThis early-phase trial tested a combination of four therapies to train the immune system to attack cancer. 17 adults with non-Hodgkin's lymphoma, metastatic breast cancer, or head and neck cancer received low-dose radiation, an immune cell booster (Flt3L), an immune activator (Po…
Matched conditions: NON-HODGKIN'S LYMPHOMA
Phase: PHASE1, PHASE2 • Sponsor: Icahn School of Medicine at Mount Sinai • Aim: Disease control
Last updated May 26, 2026 05:44 UTC
-
New combo therapy tackles tough blood cancers
Disease control CompletedThis study tested the drug nivolumab, alone or with other drugs, in 320 adults with blood cancers like lymphoma and multiple myeloma that had returned or stopped responding to prior treatments. The main goal was to check safety and side effects, especially when nivolumab was comb…
Matched conditions: NON-HODGKIN'S LYMPHOMA
Phase: PHASE1, PHASE2 • Sponsor: Bristol-Myers Squibb • Aim: Disease control
Last updated May 26, 2026 05:44 UTC
-
Can we skip the extra shot after stem cell transplant?
Disease control CompletedThis study looked at 77 people with multiple myeloma or non-Hodgkin lymphoma who had a stem cell transplant. Half got a growth factor (tbo-filgrastim) after transplant and half did not. The goal was to see if skipping the growth factor still allowed patients to leave the hospital…
Matched conditions: NON-HODGKIN'S LYMPHOMA
Phase: PHASE2 • Sponsor: Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University • Aim: Disease control
Last updated May 22, 2026 14:04 UTC